Cure My Disease

Don't miss your cure!

 Log in / Sign up

Two-Step PET scan aims to spot hidden colorectal cancer spread

NCT ID NCT02587247

Diagnosis Sponsor: Nantes University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 14, 2026 · Last updated Sep 15, 2026 · Updated 1 time

Summary

Researchers test a two-step PET scan to find colorectal cancer that has spread to the liver or other organs. The scan uses an antibody that sticks to a protein called CEA on cancer cells, then a radioactive peptide that lights up those cells. Adults with colorectal cancer that may be removable by surgery or heat ablation can join. The trial compares this scan to standard imaging to see which finds more tumors.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a two-step imaging agent made of a bispecific anti-CEA antibody (TF2) and a Gallium-68 labeled peptide (IMP-288)
What this could lead to
If it works, doctors could spot colorectal cancer metastases more accurately and decide who benefits from surgery or heat ablation.
What could go wrong
This is a small Phase 2 trial with 11 planned participants, so results may not apply broadly. The imaging agent may miss small tumors or produce false positives.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

11 people

The number who actually took part.

Start date

Mar 2016

Finished

Jan 2017

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Existence of one or more metastases of of colorectal cancer (CRC) expressing the CEA , potentially accessible by surgical or thermo resection at the moment of the diagnosis or at relapse. OR * Isolated and progressive elevation of plasma CEA during the monitoring of CRC with high metastatic risk * More than 18 years * Negative pregnancy test for women of childbearing age. Women of childbearing age should take effective continuous contraception for 3 months. * At least 4 weeks after the last treatment and after recovery of potential toxicity * Karnofsky more than 70 or ECOG 0-1 * Life expectancy of at least 6 months * CEA positive immunohistochemistry or plasma CEA supperior or equal to the normal level * Creatinin less or equal 200 micromol/L * Signed informed consent * geographical proximity Exclusion Criteria: * Pregnancy or breastfeeding * Serious illness or comorbidity assessed risk * History of other cancer within 5 years, with the exception of skin carcinomas other than melanomas or in-situ carcinoma of the cervix * Anti-antibody presence in patients who have already received antibody * Hypersensitivity to antibodies or proteins * Intellectual inability to sign the informed consent * Insulin-dependent diabetic patient or non-insulin dependent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metastatic colorectal cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metastatic colorectal cancer

Contacts and locations

Locations

  • CHU

    Nantes, 44093, France

  • Institut de cancérologie de l'Ouest

    Saint-Herblain, 44805, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.